Clinical Trial Update: Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Methylphenidate Transdermal System (MTS) to Concerta in children aged 6-12 with ADHD has completed, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)
• Methylphenidate Transdermal System (MTS) (methylphenidate)

Snippet

Sponsor: Noven Therapeutics | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED